Canine Allergic Skin Disease: Diagnostic Workup and Long-Term Planning

Bottom line

Canine atopic dermatitis is a clinical diagnosis reached after compatible history and examination plus exclusion or control of competing pruritic disease. Allergy testing does not diagnose atopy. At the first visit and at loss of control, return to a minimum dermatologic database, identify secondary infection and ectoparasites, and separate diagnostic interventions from symptomatic treatment.[1]

Build the long-term plan around measurable function, flare instructions, adherence, safety monitoring, and predefined reassessment. Therapeutic choice follows patient phenotype and owner constraints; it should not substitute for a defensible diagnostic process.

Define phenotype and trajectory

Document age at onset, seasonality, initial lesion distribution, pruritus before lesions, household or human pruritus, travel, contact animals, parasite prevention, diet and flavored exposures, previous therapies with dose and response, otitis history, gastrointestinal signs, and environmental pattern. Map primary and secondary lesions, distribution, otic findings, pododermatitis, and pain.

Use serial photographs, body weight, lesion scoring where practical, and a repeatable owner-reported itch or quality-of-life measure. A validated questionnaire has demonstrated that both canine and caregiver quality of life and treatment satisfaction can be captured longitudinally.[2] Define success as functional control and acceptable adverse-effect burden rather than zero visible lesions.

Minimum dermatologic database

AAHA recommends flea combing, skin scrapings, skin and ear cytology as indicated, and review of prior antimicrobial therapy as part of the minimum workup.[1] Add hair examination, dermatophyte testing, bacterial culture, biopsy, endocrine testing, or other diagnostics according to lesion pattern and response.

Cytology should answer a lesion-specific question and be repeated when the phenotype or response changes. Treat clinically relevant bacterial and Malassezia overgrowth while correcting the inflammatory and barrier disease that enabled recurrence. Deep infection, rods, poor response, prior antimicrobial exposure, or unusual lesions should lower the threshold for culture.

Evaluate ectoparasite exposure and product administration rather than accepting “on prevention” as proof of coverage. Institute an appropriately broad, adherence-verifiable parasite trial when indicated, including in-contact animals and environmental management.

Diagnostic diet trial

When cutaneous adverse food reaction remains plausible, select a complete diet with a defensible ingredient history and conduct a strict elimination trial followed, when medically appropriate, by controlled provocation. Audit treats, chews, supplements, flavored preventives, medications, scavenging, shared bowls, and household access before interpreting failure.

Improvement during elimination is not sufficient to identify a food trigger without a compatible recurrence on challenge. Conversely, accidental exposure, poor intake, concurrent infection, or simultaneous treatment changes can make a true response uninterpretable. Record the diagnostic question, allowed items, trial dates, rescue plan, and challenge strategy in writing.

Atopy and allergy testing

Once competing causes are controlled, a compatible chronic or recurrent pruritic phenotype supports canine atopic dermatitis. Intradermal or serum allergen testing is used to select allergens for allergen-specific immunotherapy; neither test establishes the diagnosis.[1] Interpret results against exposure history and test performance rather than labeling every positive allergen clinically causal.

Discuss immunotherapy as a long-horizon disease-modifying option with variable response and delayed assessment. Symptomatic control may still be needed during induction. For drug-specific evidence and safety considerations, see the oclacitinib hub, lokivetmab hub, and cyclosporine hub.

Choose multimodal management

Match therapy to flare versus maintenance needs, infection status, age, comorbidities, concurrent drugs, owner capacity, cost, speed of onset, and monitoring requirements. Topical therapy, bathing, barrier support, parasite control, allergen avoidance where realistic, systemic antipruritic therapy, and immunotherapy can occupy different roles. ICADA guidance supports individualized multimodal care rather than a single universal sequence.[3]

Avoid changing several variables at once unless severity requires it. If multiple interventions begin together, explicitly mark which are diagnostic, which are rescue measures, and when each will be reassessed. Provide safe stop rules and discourage owner escalation of leftover glucocorticoids, antibiotics, or topical products.

Loss-of-control algorithm

When a previously controlled dog flares, verify treatment delivery and parasite prevention; repeat examination and lesion-directed cytology; reassess ears and feet; check for ectoparasites; and review new exposures, diet breaches, contact animals, and season. Do not equate response to an antimicrobial, antipruritic, or glucocorticoid with etiologic confirmation.

Escalate diagnostics when lesions are atypical, infection is deep or recurrent, cytology and clinical response conflict, systemic signs emerge, or the expected treatment trajectory fails. Dermatology referral is appropriate for diagnostic uncertainty, repeated infections, unacceptable adverse effects, need for intradermal testing or immunotherapy, or inadequate control despite an audited plan.

Monitoring and communication

Set a recheck interval based on severity and intervention. Track sleep, activity, licking, scratching, otic pain, lesion distribution, infections, body weight, and adverse effects. Schedule laboratory monitoring appropriate to the selected medication and patient rather than applying one protocol to every therapy.

Give owners separate baseline and flare instructions: what to continue, what may be restarted, which signs require cytology or examination, and when emergency care is needed. At every recheck, reconcile products and diets, then simplify the plan when possible.

Frequently Asked Questions

Does serum allergy testing diagnose canine atopy?

No. Serum and intradermal testing support allergen selection for immunotherapy after a clinical diagnosis; they do not diagnose atopy.[1]

What belongs in the minimum dermatologic database?

History and examination plus flea combing, skin scrapings, and lesion-appropriate skin and ear cytology form the core; additional tests follow phenotype and response.[1]

When should bacterial culture be prioritized?

Consider it for deep infection, rods, recurrent or poorly responsive disease, prior substantial antimicrobial exposure, or an atypical presentation.

How is a diet trial confirmed?

Use strict elimination followed, when appropriate, by controlled provocation that reproduces compatible signs. Improvement alone can be confounded.

Can response to an antipruritic confirm atopy?

No. Clinical response helps management but is not etiologically specific and does not exclude parasites, infection, or food reaction.

When is referral appropriate?

Refer for diagnostic uncertainty, recurrent infection, uncontrolled disease, treatment-limiting adverse effects, or immunotherapy and advanced diagnostic needs.

What should be measured longitudinally?

Track itch-related function, lesion distribution, otitis and infection frequency, rescue use, adverse effects, adherence, and dog and caregiver quality of life.

References

1. American Animal Hospital Association — 2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines. https://www.aaha.org/resources/2023-aaha-management-of-allergic-skin-diseases-in-dogs-and-cats-guidelines/
2. Noli et al., Veterinary Dermatology — Development and validation of a canine allergic dermatitis quality-of-life and treatment-satisfaction questionnaire. https://pubmed.ncbi.nlm.nih.gov/38361109/
3. Olivry et al., BMC Veterinary Research — Treatment of canine atopic dermatitis: 2015 updated ICADA guidelines. https://pmc.ncbi.nlm.nih.gov/articles/PMC4537558/